Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents

1Ghosh AK, Brindisi M. Urea derivatives in modern drug discovery and medicinal chemistry. J Med Chem 2020;63:2751–88. doi: 10.1021/acs.jmedchem.9b01541 Ghosh AK Brindisi M Urea derivatives in modern drug discovery and medicinal chemistry J Med Chem 2020632751 88 doi 10.1021/acs.jmedchem.9b01541726609731789518Open DOISearch in Google Scholar

2Chaturvedi D. Role of organic carbamates in anticancer drug design. In: Brahmachari G, editor. Chemistry and pharmacology of naturally occurring bioactive compounds. 1^st ed. Boca Raton (FL): CRC Press; 2013. p. 117–40. doi: 10.1201/b13867-6 Chaturvedi D Role of organic carbamates in anticancer drug design In Brahmachari G editor Chemistry and pharmacology of naturally occurring bioactive compounds. 1^st ed Boca Raton (FL) CRC Press 2013 p 117 40 doi 10.1201/b13867-6Open DOISearch in Google Scholar

3Strzelczyk A, Mann C, Willems LM. Rosenow F, Bauer S. Cenobamate for the treatment of focal epilepsies. Expert Opin Pharmacother 2020. doi: 10.1080/14656566.2020.1803830 Strzelczyk A Mann C Willems LM Rosenow F Bauer S Cenobamate for the treatment of focal epilepsies Expert Opin Pharmacother 2020 doi 10.1080/14656566.2020.180383032812825Open DOISearch in Google Scholar

4Keam SJ. Cenobamate: First approval. Drugs 2020;80:73–8. doi: 10.1007/s40265-019-01250-6 Keam SJ Cenobamate: First approval Drugs 20208073 8 doi 10.1007/s40265-019-01250-631933170Open DOISearch in Google Scholar

5Adams P, Baron FA. Esters of carbamic acid. Chem Rev 1965;65:567–602. doi: 10.1021/cr60237a002 Adams P Baron FA Esters of carbamic acid Chem Rev 196565567 602 doi 10.1021/cr60237a002Open DOISearch in Google Scholar

6Eddleston M, Clark RF. Insecticides: organic phosphorus compounds and carbamates. In: Hoffman RS, Howland MA, Lewin NA, Nelson LS, editors. Goldfrank’s toxicologic emergencies. 9^th ed. New York: McGraw-Hill; 2011. p. 1450–60. Eddleston M Clark RF Insecticides: organic phosphorus compounds and carbamates In Hoffman RS Howland MA Lewin NA Nelson LS editors Goldfrank’s toxicologic emergencies. 9^th ed New York McGraw-Hill 2011 p 1450 60Search in Google Scholar

7Chaturvedi D. Perspectives on the synthesis of organic carbamates. Tetrahedron 2012;68:15–45. doi: 10.1016/j. tet.2011.10.001 Chaturvedi D Perspectives on the synthesis of organic carbamates Tetrahedron 20126815 45 doi 10.1016/j.tet.2011.10.001Open DOISearch in Google Scholar

8Ghosh AK, Brindisi M. Organic carbamates in drug design and medicinal chemistry. J Med Chem 2015;58:2895–940. doi: 10.1021/jm501371s Ghosh AK Brindisi M Organic carbamates in drug design and medicinal chemistry J Med Chem 2015582895 940 doi 10.1021/jm501371s439337725565044Open DOISearch in Google Scholar

9DeRuiter J. Amides and related functional groups. Principles of Drug Action 1, 2005 [displayed 20 April 2019]. Available at http://webhome.auburn.edu/~deruija/pda1_amides.pdf DeRuiter J. Amides and related functional groups. Principles of Drug Action 1 2005 [displayed 20 April 2019] Available at http://webhome.auburn.edu/~deruija/pda1_amides.pdfSearch in Google Scholar

10Vagner J, Qu H, Hruby VJ. Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol 2008;12:292–6. doi: 10.1016/j.cbpa.2008.03.009 Vagner J Qu H Hruby VJ Peptidomimetics, a synthetic tool of drug discovery Curr Opin Chem Biol 200812292 6 doi 10.1016/j.cbpa.2008.03.009251556418423417Open DOISearch in Google Scholar

11Karaman R. Prodrugs design based on inter- and intramolecular chemical processes. Chem Biol Drug Des 2013;82:643–68. doi: 10.1111/cbdd.12224 Karaman R Prodrugs design based on inter- and intramolecular chemical processes Chem Biol Drug Des 201382643 68 doi 10.1111/cbdd.1222423998799Open DOISearch in Google Scholar

12Yılmaz S, Akbaba J, Özgeriş B, Polat Köse L, Göksu S, Gülçin I, Alwasel SH, Supuran CT. Synthesis and inhibitory properties of some carbamates on carbonic anhydrase and acetylcholine esterase. J Enzyme Inhib Med Chem 2016;31:1484–91. doi: 10.3109/14756366.2016.1149477 Yılmaz S Akbaba J Özgeriş B Polat Köse L Göksu S Gülçin I Alwasel SH Supuran CT Synthesis and inhibitory properties of some carbamates on carbonic anhydrase and acetylcholine esterase J Enzyme Inhib Med Chem 2016311484 91 doi 10.3109/14756366.2016.114947726985691Open DOISearch in Google Scholar

13Moraczewski AL, Banaszynski LA, From AM, White CE, Smith BD. Using hydrogen bonding to control carbamate C-N rotamer equilibria. J Org Chem 1998;63:7258–62. doi: 10.1021/jo980644d Moraczewski AL Banaszynski LA From AM White CE Smith BD Using hydrogen bonding to control carbamate C-N rotamer equilibria J Org Chem 1998637258 62 doi 10.1021/jo980644d11672368Open DOISearch in Google Scholar

14Kaur D, Sharma P, Bharatam PV. Amide resonance in thioand seleno- carbamates: A theoretical study. J Mol Struct 2005;757:149–53. doi: 10.1016/j.theochem.2005.09.019 Kaur D Sharma P Bharatam PV Amide resonance in thioand seleno- carbamates: A theoretical study J Mol Struct 2005757149 53 doi 10.1016/j.theochem.2005.09.019Open DOISearch in Google Scholar

15Deetz MJ, Forbes CC, Jonas M, Malerich JP, Smith BD, Wiest O. Unusually low barrier to carbamate C-N rotation. J Org Chem 2002;67:3949–52. doi: 10.1021/jo025554u Deetz MJ Forbes CC Jonas M Malerich JP Smith BD Wiest O Unusually low barrier to carbamate C-N rotation J Org Chem 2002673949 52 doi 10.1021/jo025554u12027723Open DOISearch in Google Scholar

16Jung T, Do HJ, Son J, Song JH, Cha W, Kim YJ, Lee KK, Kwak K. Hindered C-N bond rotation in triazinyl dithiocarbamates. J Mol Struct 2018;1152:215–22. doi: 10.1016/j.molstruc.2017.09.063 Jung T Do HJ Son J Song JH Cha W Kim YJ Lee KK Kwak K Hindered C-N bond rotation in triazinyl dithiocarbamates J Mol Struct 20181152215 22 doi 10.1016/j.molstruc.2017.09.063Open DOISearch in Google Scholar

17Dugave C, Demange L. Cis-trans isomerization of organic molecules and biomolecules: implications and applications. Chem Rev 2003;103:2475–532. doi: 10.1021/cr0104375 Dugave C Demange L Cis-trans isomerization of organic molecules and biomolecules: implications and applications Chem Rev 20031032475 532 doi 10.1021/cr010437512848578Open DOISearch in Google Scholar

18Lauvergnat D, Hiberty PC. Role of conjugation in the stabilities and rotational barriers of formamide and thioformamide. An ab initio valence-bond study. J Am Chem Soc 1997;119:9478–82. doi: 10.1021/ja9639426 Lauvergnat D Hiberty PC Role of conjugation in the stabilities and rotational barriers of formamide and thioformamide. An ab initio valence-bond study J Am Chem Soc 19971199478 82 doi 10.1021/ja9639426Open DOISearch in Google Scholar

19Marcovici-Mizrahi D, Gottlieb HE, Marks V, Nudelman A. On the stabilization of the syn-rotamer of amino acid carbamate derivatives by hydrogen bonding. J Org Chem 1996;61:8402–6. doi: 10.1021/jo961446u Marcovici-Mizrahi D Gottlieb HE Marks V Nudelman A On the stabilization of the syn-rotamer of amino acid carbamate derivatives by hydrogen bonding J Org Chem 1996618402 6 doi 10.1021/jo961446uOpen DOISearch in Google Scholar

20Woolley GA, Jaikaran ASI, Zhang Z, Peng S. Design of regulated ion channels using measurements of cis-trans isomerization in single molecules. J Am Chem Soc 1995;117:4448–54. doi: 10.1021/ja00121a002 Woolley GA Jaikaran ASI Zhang Z Peng S Design of regulated ion channels using measurements of cis-trans isomerization in single molecules J Am Chem Soc 19951174448 54 doi 10.1021/ja00121a002Open DOISearch in Google Scholar

21Vacondio F, Silva C, Mor M, Testa B. Qualitative structure-metabolism relationship in the hydrolysis of carbamates. Drug Metab Rev 2010;42:551–89. doi: 10.3109/03602531003745960 Vacondio F Silva C Mor M Testa B Qualitative structure-metabolism relationship in the hydrolysis of carbamates Drug Metab Rev 201042551 89 doi 10.3109/0360253100374596020441444Open DOISearch in Google Scholar

22Reiner E, Škrinjarić-Špoljar M. Enzimska razgradnja karbamata [Carbamate metabolism, in Croatian]. Arh Hig Rada Toksikol 1968;19:251–8 [displayed 20 March 2019]. Available at https://hrcak.srce.hr/176452 Reiner E Škrinjarić-Špoljar M Enzimska razgradnja karbamata [Carbamate metabolism, in Croatian] Arh Hig Rada Toksikol 196819251 8 [displayed 20 March 2019]. Available at https://hrcak.srce.hr/176452Search in Google Scholar

23Mattarei A, Azzolini M, Zoratti M, Biasutto L, Paradisi C. N-monosubstituted methoxy-oligo(ethylene glycol) carbamate ester prodrugs of resveratrol. Molecules 2015;20:16085–102. doi: 10.3390/molecules200916085 Mattarei A Azzolini M Zoratti M Biasutto L Paradisi C. N-monosubstituted methoxy-oligo(ethylene glycol) carbamate ester prodrugs of resveratrol Molecules 20152016085 102 doi 10.3390/molecules200916085633231226404221Open DOISearch in Google Scholar

24Parise Filho R, Polli MC, Garcia M, Barberato-Filho S. Prodrugs available on the Brazilian pharmaceutical market and their corresponding bioactivation pathways. Braz J Pharm Sci 2010;46:393–420. doi: 10.1590/S1984-82502010000300003 Parise Filho R Polli MC Garcia M Barberato-Filho S Prodrugs available on the Brazilian pharmaceutical market and their corresponding bioactivation pathways Braz J Pharm Sci 201046393 420 doi 10.1590/S1984-82502010000300003Open DOISearch in Google Scholar

25King AM, Aaron CK. Organophosphate and carbamate poisoning. Emerg Med Clin North Am 2015;33:133–51. doi: 10.1016/j.emc.2014.09.010 King AM Aaron CK Organophosphate and carbamate poisoning Emerg Med Clin North Am 201533133 51 doi 10.1016/j.emc.2014.09.010Open DOISearch in Google Scholar

26Maki T, Tsuritani T, Yasukata T. A mild method for the synthesis of carbamateprotected guanidines using the Burgess reagent. Org Lett 2014;16:1868–71. doi: 10.1021/ol5002208 Maki T Tsuritani T Yasukata T A mild method for the synthesis of carbamateprotected guanidines using the Burgess reagent Org Lett 2014161868 71 doi 10.1021/ol5002208Open DOISearch in Google Scholar

27Hong JY, Seo UR, Chung YK. Synthesis of carbamates from amines and N-tosylhydrazones under atmospheric pressure of carbon dioxide without an external base. Org Chem Front 2016;3:764–7. doi: 10.1039/c6qo00111d Hong JY Seo UR Chung YK Synthesis of carbamates from amines and N-tosylhydrazones under atmospheric pressure of carbon dioxide without an external base Org Chem Front 20163764 7 doi 10.1039/c6qo00111dOpen DOISearch in Google Scholar

28Sogorb MA, Vilanova E. Enzymes involved in the detoxification of organophosphorus, carbamate and pyrethroid insecticides through hydrolysis. Toxicol Lett 2002;128:215–28. doi: 10.1016/s0378-4274(01)00543-4 Sogorb MA Vilanova E Enzymes involved in the detoxification of organophosphorus, carbamate and pyrethroid insecticides through hydrolysis Toxicol Lett 2002128215 28 doi 10.1016/s0378-4274(01)00543-4Open DOISearch in Google Scholar

29Nunes G, Barceló D. Analysis of carbamate insecticides in foodstuffs using chromatography and immunoassay techniques. Trends Anal Chem1999;18:99–107. doi: 10.1016/S0165-9936(98)00076-4 Nunes G Barceló D Analysis of carbamate insecticides in foodstuffs using chromatography and immunoassay techniques Trends Anal Chem 19991899 107 doi 10.1016/S0165-9936(98)00076-4Open DOISearch in Google Scholar

30Wang Q, Lemley AT. Competitive degradation and detoxification of carbamate insecticides by membrane anodic fenton treatment. J Agric Food Chem 2003;51:5382–90. doi: 10.1021/jf034311f Wang Q Lemley AT Competitive degradation and detoxification of carbamate insecticides by membrane anodic fenton treatment J Agric Food Chem 2003515382 90 doi 10.1021/jf034311f12926887Open DOISearch in Google Scholar

31Plastics Europe. Plastics-the facts 2014/2015. An analysis of European plastics production, demand and waste data [displayed 17 May 2020]. Available at https://www.plasticseurope.org/application/files/5515/1689/9220/2014plastics_the_facts_PubFeb2015.pdf Plastics Europe. Plastics-the facts 2014/2015 An analysis of European plastics production, demand and waste data [displayed 17 May 2020]. Available at https://www.plasticseurope.org/application/files/5515/1689/9220/2014plastics_the_facts_PubFeb2015.pdfSearch in Google Scholar

32Akindoyo JO, Beg MDH, Ghazali S, Islam MR, Jeyaratnam N, Yuvaray AR. Polyurethane types, synthesis and applications-a review. RSC Adv 2016;6;114453–82. doi: 10.1039/C6RA14525F Akindoyo JO Beg MDH Ghazali S Islam MR Jeyaratnam N Yuvaray AR Polyurethane types, synthesis and applications-a review RSC Adv 20166114453 82 doi 10.1039/C6RA14525FOpen DOISearch in Google Scholar

33Pittelkow M, Lewinsky R, Christensen JB. Selective synthesis of carbamate protected polyamines using alkyl phenyl carbonates. Synthesis 2002;15:2195–2202. doi: 10.1055/s-2002-34859 Pittelkow M Lewinsky R Christensen JB Selective synthesis of carbamate protected polyamines using alkyl phenyl carbonates Synthesis 2002152195 2202 doi 10.1055/s-2002-34859Open DOISearch in Google Scholar

34Dhanapal D, Rebheka G, Palanivel S, Srinivasan AK. A comparative study on modified epoxy and glycidyl carbamate coatings for corrosion and fouling prevention. Surf Innov 2015;3:127–39. doi: 10.1680/si.13.00025 Dhanapal D Rebheka G Palanivel S Srinivasan AK A comparative study on modified epoxy and glycidyl carbamate coatings for corrosion and fouling prevention Surf Innov 20153127 39 doi 10.1680/si.13.00025Open DOISearch in Google Scholar

35Grube A, Donaldson D, Kiely T, Wu L. Pesticides industry sales and usage 2006 and 2007 market estimates [displayed 15 May 2020]. Availabile at https://www.epa.gov/pesticides/pesticides-industry-sales-and-usage-2006-and-2007-market-estimates Grube A Donaldson D Kiely T Wu L Pesticides industry sales and usage 2006 and 2007 market estimates [displayed 15 May 2020]. Availabile at https://www.epa.gov/pesticides/pesticides-industry-sales-and-usage-2006-and-2007-market-estimatesSearch in Google Scholar

36Wharfe J. Historical perspective and overview. In: Thompson KC, Wadhia K, Loibner AP, editors. Environmental toxicity testing. 1^st ed. Oxford: Blackwell Publishing Ltd.; 2005. p. 1–32. Wharfe J Historical perspective and overview In Thompson KC Wadhia K Loibner AP editors Environmental toxicity testing. 1^st ed Oxford Blackwell Publishing Ltd 2005 p 1 3210.1002/9781444305531.ch1Search in Google Scholar

37Proudfoot A. The early toxicology of physostigmine. Toxicol Rev 2006;25:99–138. doi: 10.2165/00139709-200625020-00004 Proudfoot A The early toxicology of physostigmine Toxicol Rev 20062599 138 doi 10.2165/00139709-200625020-0000416958557Open DOISearch in Google Scholar

38Gupta RC. Classification and uses of organophosphates and carbamates. In: Gupta RC, editor. Toxicology of oganophosphate & carbamate compounds. 1^st ed. Waltham (MA): Academic Press; 2006. p. 5–24. doi: 10.1016/b978-012088523-7/50003-X Gupta RC Classification and uses of organophosphates and carbamates In Gupta RC editor Toxicology of oganophosphate & carbamate compounds. 1^st ed Waltham (MA) Academic Press 2006 p 5 24 doi 10.1016/b978-012088523-7/50003-XOpen DOISearch in Google Scholar

39Sun B, Straubinger RM, Lovell JF. Current taxane formulations and emerging cabazitaxel delivery systems. Nano Res 2018;11:5193–218. doi: 10.1007/s12274-018-2171-0 Sun B Straubinger RM Lovell JF Current taxane formulations and emerging cabazitaxel delivery systems Nano Res 2018115193 218 doi 10.1007/s12274-018-2171-0Open DOISearch in Google Scholar

40Avendaño C, Menéndez JC. Anticancer drugs that interact with the DNA minor groove. In: Avendaño C, Menéndez JC, editors. Medicinal chemistry of anticancer drugs. 2^nd ed. Elsevier Science, 2015. p. 243–71. doi: 10.1016/B978-0-444-62649-3.00006-5 Avendaño C Menéndez JC Anticancer drugs that interact with the DNA minor groove In Avendaño C Menéndez JC editors Medicinal chemistry of anticancer drugs. 2^nd ed Elsevier Science 2015 p 243 71 doi 10.1016/B978-0-444-62649-3.00006-5Open DOISearch in Google Scholar

41Meanwell NA, Belema M. The discovery and development of daclatasvir: an inhibitor of the hepatitis C virus NS5A replication complex. Top Med Chem 2019;32:27–56. doi: 10.1007/7355_2018_47 Meanwell NA Belema M The discovery and development of daclatasvir: an inhibitor of the hepatitis C virus NS5A replication complex Top Med Chem 20193227 56 doi 10.1007/7355_2018_47Open DOISearch in Google Scholar

42Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado J. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm 2004;272:29–36. doi: 10.1016/j.ijpharm.2003.11.030 Daniel-Mwambete K Torrado S Cuesta-Bandera C Ponce-Gordo F Torrado J The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs Int J Pharm 200427229 36 doi 10.1016/j.ijpharm.2003.11.03015019066Open DOISearch in Google Scholar

43See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician 2008;78:365–70. PMID: 18711953 See S Ginzburg R Choosing a skeletal muscle relaxant Am Fam Physician 200878365 70 PMID: 18711953Search in Google Scholar

44Kung CH, Kwon CH. Carbamate derivatives of felbamate as potential anticonvulsant agents. Med Chem Res 2009;19:498–513. doi: 10.1007/s00044-009-9208-6 Kung CH Kwon CH Carbamate derivatives of felbamate as potential anticonvulsant agents Med Chem Res 200919498 513 doi 10.1007/s00044-009-9208-6Open DOISearch in Google Scholar

45Aícua-Rapún I, André P, Rossetti AO, Ryvlin P, Hottinger AF, Decosterd LA, Buclin T, Novy J. Therapeutic drug monitoring of newer antiepileptic drugs: a randomized trial for dosage adjustment. Ann Neurol 2020;87:22–9. doi: 10.1002/ana.25641 Aícua-Rapún I André P Rossetti AO Ryvlin P Hottinger AF Decosterd LA Buclin T Novy J Therapeutic drug monitoring of newer antiepileptic drugs: a randomized trial for dosage adjustment Ann Neurol 20208722 9 doi 10.1002/ana.2564131714640Open DOISearch in Google Scholar

46Flynn S, Babi A. Anticonvulsants. In: Dowd F, Johnson B, Mariotti A, authors. Pharmacology and therapeutics for dentistry. 7^th ed. Chapter 12. St. Louis: Elsevier Inc.; 2017. p. 176–92. Flynn S Babi A Anticonvulsants In Dowd F Johnson B Mariotti A authors Pharmacology and therapeutics for dentistry. 7^th ed. Chapter 12 St. Louis Elsevier Inc 2017 p 176 9210.1016/B978-0-323-39307-2.00012-6Search in Google Scholar

47Rautio J, Meanwell N, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discov 2018;17:559–87. doi: 10.1038/nrd.2018.46 Rautio J Meanwell N Di L Hageman MJ The expanding role of prodrugs in contemporary drug design and development Nat Rev Drug Discov 201817559 87 doi 10.1038/nrd.2018.46Open DOISearch in Google Scholar

48Ray S, Chaturvedi D. Application of organic carbamates in drug design. Part 1: anticancer agents - recent reports. Drugs Fut 2004;29:343. doi: 10.1358/dof.2004.029.04.787236 Ray S Chaturvedi D Application of organic carbamates in drug design. Part 1: anticancer agents - recent reports Drugs Fut 200429343 doi 10.1358/dof.2004.029.04.787236Open DOISearch in Google Scholar

49Kim RY, Yau MC, Galpin JD, Seebohm G, Ahern CA, Pless SA, Kurata HT. Atomic basis for therapeutic activation of neuronal potassium channels. Nat Commun 2015;6:8116. doi: 10.1038/ncomms9116 Kim RY Yau MC Galpin JD Seebohm G Ahern CA Pless SA Kurata HT Atomic basis for therapeutic activation of neuronal potassium channels Nat Commun 201568116 doi 10.1038/ncomms9116Open DOISearch in Google Scholar

50Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229–39. doi: 10.1016/S1470-2045(05)70094-2 Montero A Fossella F Hortobagyi G Valero V Docetaxel for treatment of solid tumours: a systematic review of clinical data Lancet Oncol 20056229 39 doi 10.1016/S1470-2045(05)70094-2Open DOISearch in Google Scholar

51Wolkenberg SE, Boger DL. Mechanisms of in situ activation for DNA-targeting antitumor agents. Chem Rev 2002;102:2477–96. doi: 10.1021/cr010046q Wolkenberg SE Boger DL Mechanisms of in situ activation for DNA-targeting antitumor agents Chem Rev 20021022477 96 doi 10.1021/cr010046q12105933Open DOISearch in Google Scholar

52Verweij J. Docetaxel (Taxotere^TM a new anti-cancer drug with promising potential? Br J Cancer 1994;70:183–4. doi: 10.1038/bjc.1994.276 Verweij J Docetaxel (Taxotere^TM a new anti-cancer drug with promising potential? Br J Cancer 199470183 4 doi 10.1038/bjc.1994.27620335067914419Open DOISearch in Google Scholar

53Lv Z, Chu Y, Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl) 2015;7:95–104. doi: 10.2147/HIV.S79956 Lv Z Chu Y Wang Y HIV protease inhibitors: a review of molecular selectivity and toxicity HIV AIDS (Auckl) 2015795 104 doi 10.2147/HIV.S79956439658225897264Open DOISearch in Google Scholar

54Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4–9. doi: 10.1093/jac/dkh029 Zeldin RK Petruschke RA Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients J Antimicrob Chemother 2004534 9 doi 10.1093/jac/dkh02914657084Open DOISearch in Google Scholar

55Achenbach CJ, Darn KM, Murphy RL. Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol 2011;6:157–77. doi: 10.2217/fvl.10.89 Achenbach CJ Darn KM Murphy RL Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults Future Virol 20116157 77 doi 10.2217/fvl.10.89312722921731578Open DOISearch in Google Scholar

56Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 2011;43:375–88. doi: 10.3109/07853890.2011.572905 Hull MW Montaner JS Ritonavir-boosted protease inhibitors in HIV therapy Ann Med 201143375 88 doi 10.3109/07853890.2011.57290521501034Open DOISearch in Google Scholar

57Croom KF, Dhilloh S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs 2009;69:1107–40. doi: 10.2165/00003495-200969080-00009 Croom KF Dhilloh S Keam SJ Atazanavir: a review of its use in the management of HIV-1 infection Drugs 2009691107 40 doi 10.2165/00003495-200969080-0000919496633Open DOISearch in Google Scholar

58Ghosh AK, Dawson ZL, Mitsuya H. Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. Bioorg Med Chem 2007;15:7576–80. doi: 10.1016/j.bmc.2007.09.010 Ghosh AK Dawson ZL Mitsuya H Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV Bioorg Med Chem 2007157576 80 doi 10.1016/j.bmc.2007.09.010211293817900913Open DOISearch in Google Scholar

59Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for refractory partial epilepsy. Cochrane Database Syst Rev 2017;7(7):CD008295. doi: 10.1002/14651858. CD008295.pub4 Shi LL Dong J Ni H Geng J Wu T Felbamate as an add-on therapy for refractory partial epilepsy Cochrane Database Syst Rev 201777CD008295 doi 10.1002/14651858.CD008295.pub4648349528718506Open DOISearch in Google Scholar

60Glue P, Banfield CR, Perhach JL, Mather GG, Racha JK, Levy RH. Pharmacokinetic interactions with felbamate: In vitro-in vivo correlation. Clin Pharmacokinet 1997;33:214–24. doi: 10.2165/00003088-199733030-00004 Glue P Banfield CR Perhach JL Mather GG Racha JK Levy RH Pharmacokinetic interactions with felbamate: In vitro-in vivo correlation Clin Pharmacokinet 199733214 24 doi 10.2165/00003088-199733030-000049314612Open DOISearch in Google Scholar

61Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbmate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;27:27–34. doi: 10.1111/j.1528-1157.1986.tb03497.x Swinyard EA Sofia RD Kupferberg HJ Comparative anticonvulsant activity and neurotoxicity of felbmate and four prototype antiepileptic drugs in mice and rats Epilepsia 19862727 34 doi 10.1111/j.1528-1157.1986.tb03497.x3004930Open DOISearch in Google Scholar

62Rho JM, Donevan SD, Rogawski MA. Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther 1997;280:1383–91. PMID: 9067327 Rho JM Donevan SD Rogawski MA Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate J Pharmacol Exp Ther 19972801383 91 PMID: 9067327Search in Google Scholar

63Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and γ-aminobutyric acid_A receptors. Ann Neurol 1994;35:229–34. doi: 10.1002/ana.410350216 Rho JM Donevan SD Rogawski MA Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and γ-aminobutyric acid_A receptors Ann Neurol 199435229 34 doi 10.1002/ana.4103502168109904Open DOISearch in Google Scholar

64Kume A, Greenfield Jr LJ, Macdonald RL, Albin RL. Felbamate inhibits [3H]t-butylbicycloorthobenzoate (TBOB) binding and enhances Cl- current at the gamma-aminobutyric AcidA (GABAA) receptor. J Pharmacol Exp Ther 1996;277:1784–92. PMID: 8667250 Kume A GreenfieldJr LJ Macdonald RL Albin RL Felbamate inhibits [3H]t-butylbicycloorthobenzoate (TBOB) binding and enhances Cl- current at the gamma-aminobutyric AcidA (GABAA) receptor J Pharmacol Exp Ther 19962771784 92 PMID: 8667250Search in Google Scholar

65Ticku MK, Kamatchi GL, Sofia RD. Effect of anticonvulsant felbamate on GABA_A receptor system. Epilepsia 1991;32:389–91. doi: 10.1111/j.1528-1157.1991.tb04667.x Ticku MK Kamatchi GL Sofia RD Effect of anticonvulsant felbamate on GABA_A receptor system Epilepsia 199132389 91 doi 10.1111/j.1528-1157.1991.tb04667.x1646101Open DOISearch in Google Scholar

66Wisden W, Laurie UJ, Monyer H, Seeburg PH. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992;12:1040–62. doi: 10.1523/JNEUROSCI.12-03-01040.1992 Wisden W Laurie UJ Monyer H Seeburg PH The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon J Neurosci 1992121040 62 doi 10.1523/JNEUROSCI.12-03-01040.1992Open DOISearch in Google Scholar

67Porter RJ, Nohria V, Rundfeldt C. Retigabine. Neurotherapeutics 2007;4:149–54. doi: 10.1016/j. nurt.2006.11.012 Porter RJ Nohria V Rundfeldt C Retigabine Neurotherapeutics 20074149 54 doi 10.1016/j.nurt.2006.11.012747968917199031Open DOISearch in Google Scholar

68Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the K_v7.2 KCNQ2 channel by binding to its activation gate. Mol Pharmacol 2005;67:1009–17. doi: 10.1124/mol.104.010793 Wuttke TV Seebohm G Bail S Maljevic S Lerche H The new anticonvulsant retigabine favors voltage-dependent opening of the K_v7.2 KCNQ2 channel by binding to its activation gate Mol Pharmacol 2005671009 17 doi 10.1124/mol.104.01079315662042Open DOISearch in Google Scholar

69Sharma R, Nakamura M, Neupane C, Jeon BH, Shinc H, Melnick SM, Glenn KJ, Jang IS, Park JB. Positive allosteric modulation of GABA_A receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol 2020:879:173117. doi: 10.1016/j.ejphar.2020.173117 Sharma R Nakamura M Neupane C Jeon BH Shinc H Melnick SM Glenn KJ Jang IS Park JB Positive allosteric modulation of GABA_A receptors by a novel antiepileptic drug cenobamate Eur J Pharmacol 2020879173117 doi 10.1016/j.ejphar.2020.17311732325146Open DOISearch in Google Scholar

70Haake A, Nguyen K, Friedman L, Chakkamparambil B, Grossberg GT. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf 2020;19:147–57. doi: 10.1080/14740338.2020.1721456 Haake A Nguyen K Friedman L Chakkamparambil B Grossberg GT An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease Expert Opin Drug Saf 202019147 57 doi 10.1080/14740338.2020.172145631976781Open DOISearch in Google Scholar

71Giacobini E, editor. Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz Ltd; 2000. Giacobini E editor Cholinesterases and Cholinesterase Inhibitors London Martin Dunitz Ltd 2000Search in Google Scholar

72Bosak A, Katalinić M, Kovarik Z. Cholinesterases: structure, role, and inhibition. Arh Hig Rada Toksikol 2011;62:175–90. doi: 10.2478/10004-1254-62-2011-2107 Bosak A Katalinić M Kovarik Z Cholinesterases: structure, role, and inhibition Arh Hig Rada Toksikol 201162175 90 doi 10.2478/10004-1254-62-2011-210721705306Open DOISearch in Google Scholar

73Plata-Salaman CR, Zhao B, Teyman RE. Carbamate compounds for use in preventing or treating neurodegenerative disorders. Unites States Patent Application Publication 2002;US 2002/0165273 A1 [displayed 23 November 2020]. Available at https://patents.google.com/patent/US20020165273A1/en Plata-Salaman CR Zhao B Teyman RE Carbamate compounds for use in preventing or treating neurodegenerative disorders. Unites States Patent Application Publication 2002;US 2002/0165273 A1 [displayed 23 November 2020]. Available at https://patents.google.com/patent/US20020165273A1/enSearch in Google Scholar

74Darvesh S, Darvesh KV, McDonald RS, Mataija D, Walsh R, Mothana S, Lockridge O, Martin E. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem 2008;51:4200–12. doi: 10.1021/jm8002075 Darvesh S Darvesh KV McDonald RS Mataija D Walsh R Mothana S Lockridge O Martin E Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase J Med Chem 2008514200 12 doi 10.1021/jm800207518570368Open DOISearch in Google Scholar

75Prince M, Comas-Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer Report 2016: improving helatchare for people living with dementia: coverage, quality and costs now and in the future, Alzheimer’s disease International (ADI), 2016 [displayed 23 November 2020]. Availabile at https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdf Prince M Comas-Herrera A Knapp M Guerchet M Karagiannidou M World Alzheimer Report 2016: improving helatchare for people living with dementia: coverage, quality and costs now and in the future, Alzheimer’s disease International (ADI) 2016 [displayed 23 November 2020]. Availabile at https://www.alz.co.uk/research/WorldAlzheimerReport2016.pdfSearch in Google Scholar

76Kovacs GG, Adle-Biassette H, Milenkovic I, Cipriani S, van Scheppingen J, Aronica E. Linking pathways in the developing and aging brain with neurodegeneration. Neuroscience 2014;269:152–72. doi: 10.1016/j. neuroscience.2014.03.045 Kovacs GG Adle-Biassette H Milenkovic I Cipriani S van Scheppingen J Aronica E Linking pathways in the developing and aging brain with neurodegeneration Neuroscience 2014269152 72 doi 10.1016/j.neuroscience.2014.03.04524699227Open DOISearch in Google Scholar

77Camps P, Muñoz-Torrero D. Cholinergic drugs in pharmacotherapy of Alzheimer’s disease. Mini Rev Med Chem 2002;2:11–25. doi: 10.2174/1389557023406638 Camps P Muñoz-Torrero D Cholinergic drugs in pharmacotherapy of Alzheimer’s disease Mini Rev Med Chem 2002211 25 doi 10.2174/138955702340663812369954Open DOISearch in Google Scholar

78Bitzinger DI, Gruber M, Tummler S, Malsy M, Seyfried T, Weber F, Redel A, Graf BM, Zausig YA. In vivo effects of neostigmine and physostigmine on neutrophil functions and evaluation of acetylcholinesterase and butyrylcholinesterase as inflammatory markers during experimental sepsis in rats. Mediat Inflamm 2019;4:ID8274903. doi: 10.1155/2019/8274903 Bitzinger DI Gruber M Tummler S Malsy M Seyfried T Weber F Redel A Graf BM Zausig YA. In vivo effects of neostigmine and physostigmine on neutrophil functions and evaluation of acetylcholinesterase and butyrylcholinesterase as inflammatory markers during experimental sepsis in rats Mediat Inflamm 2019 4 ID8274903 doi 10.1155/2019/8274903636057930804708Open DOISearch in Google Scholar

79Frascogna N. Physostigmine: is there a role for this antidote in pediatric poisonings? Curr Opin Pediatr 2007;19:201–5. doi: 10.1097/MOP.0b013e32802c7be1 Frascogna N Physostigmine: is there a role for this antidote in pediatric poisonings? Curr Opin Pediatr 200719201 5 doi 10.1097/MOP.0b013e32802c7be117496766Open DOISearch in Google Scholar

80Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum 2000;43:599–603. doi: 10.1007/BF02235569 Trevisani GT Hyman NH Church JM Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction Dis Colon Rectum 200043599 603 doi 10.1007/BF0223556910826417Open DOISearch in Google Scholar

81Moghul S, Wikinson D. Use of acetylcholinesterase inhibitors in Alzheimer’s disease. Expert Rev Neurother 2001;1:61–9. doi: 10.1586/14737175.1.1.61 Moghul S Wikinson D Use of acetylcholinesterase inhibitors in Alzheimer’s disease Expert Rev Neurother 2001161 9 doi 10.1586/14737175.1.1.6119811047Open DOISearch in Google Scholar

82Kamal MA, Klein P, Luo WM, Li YZ, Holloway HW, Tweedie D, Greig NH. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem Res 2008;33;745–53. doi: 10.1007/s11064-007-9490-y Kamal MA Klein P Luo WM Li YZ Holloway HW Tweedie D Greig NH Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine Neurochem Res 200833745 53 doi 10.1007/s11064-007-9490-y520120617985237Open DOISearch in Google Scholar

83Yu QS, Holloway HW, Utsuki T, Brossi A, Greig NH. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer’s disease. J Med Chem 1999;42:1855–61. doi: 10.1021/jm980459s Yu QS Holloway HW Utsuki T Brossi A Greig NH Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer’s disease J Med Chem 1999421855 61 doi 10.1021/jm980459s10346939Open DOISearch in Google Scholar

84Greig NH, Utsuki T, Ingram DK, Wang Y, Pepeu G, Scali C, Yu Q-S, Mamczarz J, Holloway HW, Giordano T, Chen DM, Furukawa K, Sambamurti K, Brossi A, Lahiri DK. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005;102:17213–8. doi: 10.1073/pnas.0508575102 Greig NH Utsuki T Ingram DK Wang Y Pepeu G Scali C Yu Q-S Mamczarz J Holloway HW Giordano T Chen DM Furukawa K Sambamurti K Brossi A Lahiri DK Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent Proc Natl Acad Sci USA 200510217213 8 doi 10.1073/pnas.0508575102128801016275899Open DOISearch in Google Scholar

85Guo T, Gu H, Hobbs DW, Rokosz LL, Stauffer TM, Jacob B, Clader JW. Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as γ-secretase inhibitors. Bioorg Med Chem Lett 2007;17:3010–3. doi: 10.1016/j.bmcl.2007.03.055 Guo T Gu H Hobbs DW Rokosz LL Stauffer TM Jacob B Clader JW Design, synthesis, and evaluation of tetrahydroquinoline and pyrrolidine sulfonamide carbamates as γ-secretase inhibitors Bioorg Med Chem Lett 2007173010 3 doi 10.1016/j.bmcl.2007.03.05517418571Open DOISearch in Google Scholar

86Kamal MA, Qu X, Yu Q, Tweedie D, Holloway HW, Li Y, Tan Y, Greig NH. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis. J Neural Transm (Vienna) 2008;115:889–98. doi: 10.1007/s00702-008-0022-y Kamal MA Qu X Yu Q Tweedie D Holloway HW Li Y Tan Y Greig NH Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis J Neural Transm (Vienna) 2008115889 98 doi 10.1007/s00702-008-0022-y519350018235987Open DOISearch in Google Scholar

87Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436–41. doi: 10.3748/wjg.v13. i17.2436 Alter MJ Epidemiology of hepatitis C virus infection World J Gastroenterol 2007132436 41 doi 10.3748/wjg.v13.i17.2436414676117552026Open DOISearch in Google Scholar

88Chary A, Holodniy M. Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Rev Recent Clin Trials 2010;5:158–73. doi: 10.2174/157488710792007293 Chary A Holodniy M Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials Rev Recent Clin Trials 20105158 73 doi 10.2174/15748871079200729320482493Open DOISearch in Google Scholar

89Hwang J, Huang L, Cordek DG, Vaughan R, Reynolds SL, Kihara G, Raney KD, Kao CC, Cameron CE. Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol 2010;84:12480–91 doi: 10.1128/JVI.01319-10 Hwang J Huang L Cordek DG Vaughan R Reynolds SL Kihara G Raney KD Kao CC Cameron CE Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins J Virol 20108412480 91 doi 10.1128/JVI.01319-10300434020926572Open DOISearch in Google Scholar

90Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002;292:198–210. doi: 10.1006/viro.2001.1225 Shi ST Polyak SJ Tu H Taylor DR Gretch DR Lai MM Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins Virology 2002292198 210 doi 10.1006/viro.2001.122511878923Open DOISearch in Google Scholar

91Kohler JJ, Nettles JH, Amblard F, Hurwitz SJ, Bassit L, Stanton RA, Ehteshami M, Schinazi RF. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infect Drug Resist 2014:7:41–56. doi: 10.2147/IDR.S36247 Kohler JJ Nettles JH Amblard F Hurwitz SJ Bassit L Stanton RA Ehteshami M Schinazi RF Approaches to hepatitis C treatment and cure using NS5A inhibitors Infect Drug Resist 2014741 56 doi 10.2147/IDR.S36247394969824623983Open DOISearch in Google Scholar

92Lee C. Daclatasvir: potential role in hepatitis C. Drug Des Devel Ther 2013;7:1220–33. doi: 10.2147/DDDT.S40310 Lee C Daclatasvir: potential role in hepatitis C Drug Des Devel Ther 201371220 33 doi 10.2147/DDDT.S40310Open DOISearch in Google Scholar

93Cada DJ, Kim AP, Baker DE. Elbasvir/Grazoprevir. Hosp Pharm 2016;51:665–86. doi: 10.1310/hpj5108-665 Cada DJ Kim AP Baker DE Elbasvir/Grazoprevir Hosp Pharm 201651665 86 doi 10.1310/hpj5108-665Open DOISearch in Google Scholar

94Keating GM. Ombitasvir/Paritaprevir/Ritonavir: a review in chronic HCV genotype 4 infection. Drugs 2016;76:1203–11. doi: 10.1007/s40265-016-0612-1 Keating GM Ombitasvir/Paritaprevir/Ritonavir: a review in chronic HCV genotype 4 infection Drugs 2016761203 11 doi 10.1007/s40265-016-0612-1Open DOISearch in Google Scholar

95Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O’Boyle DR, Colonno RJ, Gao M, Meanwell NA, Hamann LG. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir. J Med Chem 2014;57:2013–32. doi: 10.1021/jm401836p Belema M Nguyen VN Bachand C Deon DH Goodrich JT James CA Lavoie R Lopez OD Martel A Romine JL Ruediger EH Snyder LB St Laurent DR Yang F Zhu J Wong HS Langley DR Adams SP Cantor GH Chimalakonda A Fura A Johnson BM Knipe JO Parker DD Santone KS Fridell RA Lemm JA O’Boyle DR Colonno RJ Gao M Meanwell NA Hamann LG Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir J Med Chem 2014572013 32 doi 10.1021/jm401836pOpen DOISearch in Google Scholar

96World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization [displayed 8 December 2020]. Available at: https://apps.who.int/iris/handle/10665/325771 World Health Organization World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization [displayed 8 December 2020]. Available at https://apps.who.int/iris/handle/10665/325771Search in Google Scholar

97O’Doherty DS, Shields CD. Methocarbamol-new agent in treatment of neurological and neuromuscular diseases. J Am Med Assoc 1958;167:160–3. doi: 10.1001/jama.1958.02990190014003 O’Doherty DS Shields CD Methocarbamol-new agent in treatment of neurological and neuromuscular diseases J Am Med Assoc 1958167160 3 doi 10.1001/jama.1958.02990190014003Open DOISearch in Google Scholar

98Anthelmintic benzimidazole carbamates [displayed 20 September 2020]. Available at https://patents.google.com/patent/US4512998A/en Anthelmintic benzimidazole carbamates [displayed 20 September 2020]. Available at https://patents.google.com/patent/US4512998A/enSearch in Google Scholar

99Köhler P. The biochemical basis of anthelmintic action and resistance. Int J Parasitol 2001;31:336–45. doi: 10.1016/s0020-7519(01)00131-x Köhler P The biochemical basis of anthelmintic action and resistance Int J Parasitol 200131336 45 doi 10.1016/s0020-7519(01)00131-xOpen DOISearch in Google Scholar

100Campbell WC. The chemotherapy of parasitic infections. J Parasitol 1986;72:45–61. doi: 10.2307/3281795 Campbell WC The chemotherapy of parasitic infections J Parasitol 19867245 61 doi 10.2307/3281795Open DOISearch in Google Scholar

101Giordani C, Marin GH, Perez D, Soraci A, Errecalde J. Mechanism of action of drugs with activity against multicellular parasites. Parazitologija 2017;51:294–316 [displayed 23 November 2020]. Available at http://sedici.unlp.edu.ar/bitstream/handle/10915/98772/Mechanism_of_action_of_drugs_with_activity_against_multicellular_parasites.pdf-PDFA.pdf?sequence=1&isAllowed=y Giordani C Marin GH Perez D Soraci A Errecalde J Mechanism of action of drugs with activity against multicellular parasites Parazitologija 201751294 316 [displayed 23 November 2020]. Available at http://sedici.unlp.edu.ar/bitstream/handle/10915/98772/Mechanism_of_action_of_drugs_with_activity_against_multicellular_parasites.pdf-PDFA.pdf?sequence=1&isAllowed=ySearch in Google Scholar

102Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008;7:255–70. doi: 10.1038/nrd2468 Rautio J Kumpulainen H Heimbach T Oliyai R Oh D Järvinen T Savolainen J Prodrugs: design and clinical applications Nat Rev Drug Discov 20087255 70 doi 10.1038/nrd246818219308Open DOISearch in Google Scholar

103Hahn KK, Wolff JJ, Kolaser JM. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm 2006;63:2211–7. doi: 10.2146/ajhp060155 Hahn KK Wolff JJ Kolaser JM Pharmacogenetics and irinotecan therapy Am J Health Syst Pharm 2006632211 7 doi 10.2146/ajhp06015517090741Open DOISearch in Google Scholar

104Frese S, Diamond B. Structural modification of DNA therapeutic option in SLE. Nat Rev Rheumatol 2011;7:733–8. doi: 10.1038/nrrheum.2011.153 Frese S Diamond B Structural modification of DNA therapeutic option in SLE Nat Rev Rheumatol 20117733 8 doi 10.1038/nrrheum.2011.153474540922009329Open DOISearch in Google Scholar

105Mathijessen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182–94. PMID:11489791 Mathijessen RH van Alphen RJ Verweij J Loos WJ Nooter K Stoter G Sparreboom A Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin Cancer Res 200172182 94 PMID:11489791Search in Google Scholar

106Sitar DS. Clinical pharmacokinetics of bambuterol. Clin Pharmacokinet 1996;31:246–56. doi: 10.2165/00003088-199631040-00002 Sitar DS Clinical pharmacokinetics of bambuterol Clin Pharmacokinet 199631246 56 doi 10.2165/00003088-199631040-000028896942Open DOISearch in Google Scholar

107Zhou T, Liu S, Zhao T, Zeng J, He M, Xu B, Qu S, Xu L, Tan W. Chiral analysis of bambuterol, its intermediate and active drug in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2015;997:38–44. doi: 10.1016/j.jchromb.2015.05.024 Zhou T Liu S Zhao T Zeng J He M Xu B Qu S Xu L Tan W Chiral analysis of bambuterol, its intermediate and active drug in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study J Chromatogr B Analyt Technol Biomed Life Sci 201599738 44 doi 10.1016/j.jchromb.2015.05.02426092775Open DOISearch in Google Scholar

108Svensson LA, Tunek A. The design and bioactivation of presystemically stable prodrugs. Drug Metab Rev 1998;19:165–94. doi: 10.3109/03602538809049622 Svensson LA Tunek A The design and bioactivation of presystemically stable prodrugs Drug Metab Rev 199819165 94 doi 10.3109/036025388090496223069421Open DOISearch in Google Scholar

109Yaltho TC, Ondo WG. The use of gabapentin enacarbil in the treatment of restless legs syndrome. Ther Adv Neurol Disord 2010;3:269–75. doi: 10.1177/1756285610378059 Yaltho TC Ondo WG The use of gabapentin enacarbil in the treatment of restless legs syndrome Ther Adv Neurol Disord 20103269 75 doi 10.1177/1756285610378059300266521179617Open DOISearch in Google Scholar

110Guerreiro C, Albuquerque L, Reimão S. Radiation recall myelitis following capecitabine: first case report. Clin Neurol Neurosurg 2020;196:105978. doi: 10.1016/j. clineuro.2020.105978 Guerreiro C Albuquerque L Reimão S Radiation recall myelitis following capecitabine: first case report Clin Neurol Neurosurg 2020196105978 doi 10.1016/j.clineuro.2020.10597832540712Open DOISearch in Google Scholar

111Terranova-Barberio M, Roca M, Zotti A, Leone A, Bruzzese F, Vitagliano C, Scogliamiglio G, Russo D, D’Angelo G, Franco R, Budillon A, Gennaro E. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget 2016;7:7715–31. doi: 10.18632/oncotarget.6802 Terranova-Barberio M Roca M Zotti A Leone A Bruzzese F Vitagliano C Scogliamiglio G Russo D D’Angelo G Franco R Budillon A Gennaro E Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression Oncotarget 201677715 31 doi 10.18632/oncotarget.6802488494926735339Open DOISearch in Google Scholar

112Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330–8. doi: 10.1038/nrc1074 Longley DB Harkin DP Johnston PG 5-Fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 20033330 8 doi 10.1038/nrc107412724731Open DOISearch in Google Scholar